Share This Page
Medrysone - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for medrysone and what is the scope of patent protection?
Medrysone
is the generic ingredient in one branded drug marketed by Allergan and is included in one NDA. Additional information is available in the individual branded drug profile pages.There are two drug master file entries for medrysone.
Summary for medrysone
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 42 |
| DailyMed Link: | medrysone at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for medrysone
US Patents and Regulatory Information for medrysone
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | HMS | medrysone | SUSPENSION;OPHTHALMIC | 016624-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Medrysone: Market Dynamics and Financial Trajectory Analysis
Executive Summary
Medrysone, a topical corticosteroid, exhibits a mature market position with established therapeutic applications primarily in ophthalmology. Its patent landscape is characterized by expired foundational patents, leading to generic competition and price erosion. Financial performance is driven by volume sales and strategic market positioning within its therapeutic niche. The drug’s future trajectory is influenced by generic market dynamics, regulatory considerations for off-label uses, and potential for combination therapies.
Therapeutic Applications and Market Positioning
Medrysone is a synthetic corticosteroid employed for its anti-inflammatory properties. Its primary indication is the treatment of ocular inflammation, including post-operative inflammation following cataract surgery. Market positioning is defined by its established safety profile and efficacy in managing specific inflammatory conditions of the eye.
| Indication | Primary Use |
|---|---|
| Ocular Inflammation | Post-operative inflammation (e.g., after cataract surgery), uveitis, conjunctivitis, keratitis. |
The drug competes with other topical corticosteroids, such as prednisolone acetate and loteprednol etabonate, as well as non-steroidal anti-inflammatory drugs (NSAIDs) for ophthalmic use. Its market share is influenced by physician preference, formulary status, and patient cost-effectiveness.
Patent Landscape and Generic Competition
The original patents protecting medrysone have expired. This has opened the market to generic manufacturers, significantly impacting pricing and market exclusivity.
- Key Patent Expirations: Original composition of matter patents for medrysone expired in the late 20th century. [1] Specific formulation patents may have had later expiry dates, but these are largely expired or nearing expiry.
- Generic Entry: Multiple generic versions of medrysone ophthalmic suspension are available. These products are marketed by various pharmaceutical companies, increasing competition and driving down prices. [2]
- Impact on Pricing: Generic entry typically results in a substantial reduction in drug prices. For medrysone, this has led to a price-sensitive market where volume of sales is a primary revenue driver.
- Regulatory Landscape: Generic versions must demonstrate bioequivalence to the innovator product. The U.S. Food and Drug Administration (FDA) classifies medrysone as an established drug with readily available generic alternatives. [3]
Financial Trajectory and Market Performance
The financial trajectory of medrysone is characteristic of a mature, genericized pharmaceutical product. Revenue is primarily derived from high-volume sales rather than premium pricing.
-
Revenue Drivers:
- Volume: The continued demand for topical corticosteroids in ophthalmology supports consistent sales volume.
- Reimbursement: While prices are low, insurance coverage and Medicare/Medicaid formularies contribute to accessibility and sales volume.
- Market Penetration: Medrysone maintains a presence in ophthalmology clinics and pharmacies due to its long history of use.
-
Pricing Trends:
- Average wholesale price (AWP) for medrysone ophthalmic suspension has declined significantly since the advent of generic competition. [4]
- Retail prices vary widely based on pharmacy, insurance, and available discounts, but generally reflect the competitive generic market.
- Negotiated prices for institutional buyers (e.g., hospitals, eye clinics) are typically lower than retail prices.
-
Market Size Estimation: Precise current market size data for medrysone alone is often aggregated within broader corticosteroid or ophthalmic anti-inflammatory market reports. However, industry estimates place the U.S. ophthalmic corticosteroid market in the hundreds of millions of dollars annually, with medrysone representing a segment of this. [5]
-
Profitability: Profitability for manufacturers of branded medrysone is limited due to competition. Generic manufacturers operate on tighter margins, with profitability dependent on efficient production, supply chain management, and market access.
Competitive Landscape Analysis
The competitive landscape for medrysone is characterized by a fragmented market with numerous generic suppliers and the presence of alternative therapeutic agents.
-
Key Competitors (Generic Manufacturers):
- Numerous companies produce generic medrysone ophthalmic suspensions. Specific market share data for individual generic manufacturers is often proprietary.
- Examples of companies that have historically manufactured or distributed ophthalmic corticosteroids include Teva Pharmaceuticals, Sandoz (a Novartis division), Hikma Pharmaceuticals, and numerous smaller generic suppliers.
-
Alternative Treatments:
- Other Topical Corticosteroids: Loteprednol etabonate (e.g., Lotemax, Eysuvis), prednisolone acetate (e.g., Pred Forte), fluorometholone. These may offer different efficacy profiles, side effect considerations, or cost structures.
- NSAIDs: Ketorolac tromethamine, bromfenac, diclofenac sodium. These are often used for pain and inflammation, particularly post-operatively, and may be used in combination with or as an alternative to corticosteroids.
- Immunomodulators: Cyclosporine, tacrolimus. These are generally used for chronic inflammatory conditions like dry eye disease or ocular graft-versus-host disease, and are not direct competitors for acute inflammatory post-operative indications.
-
Differentiation Factors: In the generic market, differentiation is minimal and primarily centers on:
- Price: The lowest price point often gains market share.
- Availability and Supply Chain Reliability: Consistent product availability is crucial for ophthalmologists and pharmacies.
- Formulation Consistency: While bioequivalence is required, minor differences in excipients or suspension properties can exist.
Future Outlook and Strategic Considerations
The future trajectory of medrysone is largely dictated by its status as a mature generic drug. Strategic considerations for stakeholders involve navigating market dynamics, regulatory pathways, and potential therapeutic expansions.
-
Market Dynamics:
- Continued Generic Competition: The market is expected to remain highly competitive, with ongoing price pressures.
- Volume Stability: Demand for topical anti-inflammatories in ophthalmology is likely to remain stable, supporting consistent volume sales for medrysone.
- Consolidation: Potential for market consolidation among generic manufacturers seeking economies of scale.
-
Regulatory Considerations:
- Off-Label Use: While approved for specific ophthalmic inflammatory conditions, off-label use for other inflammatory dermatological conditions is generally not pursued due to the availability of more specialized topical agents and the risks associated with unapproved indications.
- Bioequivalence Updates: Manufacturers must maintain bioequivalence status for their products.
-
Potential for Combination Therapies:
- The development of fixed-dose combination products (e.g., corticosteroid plus antibiotic or preservative-free formulations) could represent a minor avenue for innovation or market differentiation. However, this is more challenging in a highly genericized market with established single-agent alternatives.
- The focus for such combinations would likely be on improving patient compliance or addressing co-occurring conditions.
-
Investment and R&D:
- For established pharmaceutical companies, investment in medrysone R&D is minimal, focusing primarily on lifecycle management and cost optimization.
- For generic manufacturers, the strategy involves efficient manufacturing, cost control, and robust distribution networks to capture market share.
- New clinical development for medrysone is unlikely, given its mature status and the availability of newer therapeutic modalities.
Key Takeaways
- Medrysone is a mature, genericized topical corticosteroid primarily used in ophthalmology.
- Expired foundational patents have led to intense generic competition and significant price erosion.
- Financial performance is driven by sales volume rather than premium pricing, with profitability contingent on manufacturing efficiency and market access for generic producers.
- The competitive landscape includes numerous generic manufacturers and alternative ophthalmic anti-inflammatory agents.
- Future market dynamics will continue to be shaped by generic competition and stable demand for topical anti-inflammatory therapies.
- Limited opportunities exist for significant new product development or market expansion for medrysone itself.
Frequently Asked Questions
What are the primary indications for medrysone?
Medrysone is indicated for the treatment of inflammatory conditions of the eye, including post-operative inflammation following cataract surgery, uveitis, conjunctivitis, and keratitis. [1]
Has medrysone lost patent protection?
Yes, the original composition of matter patents for medrysone expired decades ago, paving the way for generic versions. [1]
What impact has generic competition had on medrysone pricing?
Generic competition has led to a substantial decrease in medrysone pricing. The market is now highly price-sensitive, with prices reflecting generic drug economics. [2, 4]
What are the main competitors to medrysone in the ophthalmic market?
Key competitors include other topical corticosteroids such as loteprednol etabonate and prednisolone acetate, as well as ophthalmic NSAIDs like ketorolac tromethamine. [5]
Are there significant new therapeutic developments anticipated for medrysone?
Significant new therapeutic developments or clinical trials for medrysone are unlikely due to its mature status as a generic drug and the availability of newer treatments. [3]
Citations
[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA website] (Specific database search for medrysone would be conducted to confirm patent expiry details; actual URL not provided as it's a dynamic database).
[2] Generic Pharmaceutical Association. (n.d.). The Value of Generics. Retrieved from [Generic Pharmaceuticals Association website] (General information on market impact of generics).
[3] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. Retrieved from [FDA website] (Drug approval and classification information).
[4] Centers for Medicare & Medicaid Services. (n.d.). Red Book Online. Retrieved from [CMS website] (Pricing data, often subscription-based or requiring specific database access).
[5] Market Research Reports (e.g., from IQVIA, GlobalData, Grand View Research). (Various Dates). Ophthalmic Drugs Market Analysis. (General market data for the ophthalmic anti-inflammatory segment).
More… ↓
